Clinical Report: Jonathan Van-Tam on COVID’s Next Phase

Overview

Professor Sir Jonathan Van-Tam discusses the ongoing burden of COVID-19 and the introduction of Sanofi's Nuvaxovid vaccine in the UK. He emphasizes the importance of continued vaccination efforts and the evolving landscape of vaccine technologies.

Background

The COVID-19 pandemic has had a profound impact on public health, particularly among vulnerable populations. Understanding the current landscape of COVID-19 prevention, including vaccination strategies, is crucial as we navigate the ongoing challenges posed by the virus. With declining vaccination rates, it is essential to explore new vaccine options to enhance public health responses.

Data Highlights

No numerical data provided in the source material.

Key Findings

• COVID-19 remains a public health concern comparable to seasonal flu, particularly for older adults.
• The lethality of COVID-19 has decreased due to vaccination and the emergence of less lethal variants.
• Sanofi's Nuvaxovid vaccine is a protein-based option introduced into the UK's Spring 2026 vaccination program.
• Protein-based vaccines deliver antigens directly, differing from mRNA vaccines that prompt the body to produce them.
• Vaccine hesitancy may persist despite the absence of scientific concerns regarding mRNA technology.
• COVID-19 peaks do not follow a seasonal pattern like flu, leading to more frequent but smaller peaks in cases.

Clinical Implications

Healthcare professionals should remain vigilant about the ongoing impact of COVID-19 and promote vaccination, particularly among vulnerable populations. The introduction of Nuvaxovid may provide an alternative for individuals hesitant about mRNA vaccines, potentially improving vaccination rates.

Conclusion

The conversation around COVID-19 vaccination continues to evolve, highlighting the need for diverse vaccine options and sustained public health efforts to mitigate the virus's impact.

References

1. Intensive Care Medicine, 2021 -- The Role of Vaccines in Managing COVID-19 in Intensive Care Settings
2. The Journal of Infectious Diseases, 2022 -- Disparate SARS-CoV-2 Infection Outcomes Abound, but What Makes SARS-CoV-2 Bound for Rebound?
3. Knee Surgery, Sports Traumatology, Arthroscopy, 2020 -- Guidelines for Preparing for Future COVID-19 Surges: Recommendations from the European Hip Society and European Knee Associates
4. The Journal of Infectious Diseases, 2022 -- How Might Insights from the COVID-19 Pandemic Influence Mortality Rates in Future Viral Outbreaks?
5. 2025–2026 COVID-19 Vaccination Guidance | Covid | CDC
6. Infectious Diseases Society of America, 2025 -- Antiviral Treatment for Mild to Moderate COVID-19 in Adults
7. Clinical Infectious Diseases, 2025 -- 2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19
8. 2025–2026 COVID-19 Vaccination Guidance | Covid | CDC
9. https://www.idsociety.org/globalassets/idsa/practice-guidelines/covid-19/treatment/antiviral-treatment-for-mild-to-moderate-covid-19-in-adults.pdf
10. 2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Pemivibart for Pre-exposure Prophylaxis, Vilobelimab for Critical Illness, and Abatacept or Infliximab for Severe or Critical Illness | Clinical Infectious Diseases | Oxford Academic